Tag: oncology

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.